For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Ignyta, Inc.

USPTO Granted Patents = 25

% Expired Patents = 68.0

EPO Patents = 5

Forward Citations = 102

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Robert L Hudkins (7 out of 72 patents)

Anthony S Drager (5 out of 9 patents)

Reddeppa Reddy Dandu (5 out of 16 patents)

4. Robert E McKean (5 out of 14 patents)

5. Peter D Brown (5 out of 9 patents)

6. Jian Chen (5 out of 7 patents)

7. Rachel Y LaBell (5 out of 6 patents)

8. Piyush R Patel (5 out of 20 patents)

9. Rabindranath Tripathy (5 out of 24 patents)

10. Catherine P Prouty (5 out of 27 patents)

11. Renee Caroline Roemmele (5 out of 24 patents)

12. Roger P Bakale (5 out of 25 patents)

13. Kurt A Josef (5 out of 28 patents)

14. Robert L Orr (3 out of 9 patents)

15. Gang Li (3 out of 6 patents)

25 patents: Sort by Forward Citations

1. 11253515 - Pharmaceutical compositions and dosage forms (2022-02-22),

2. 11007191 - Pharmaceutical compositions and dosage forms (2021-05-18),

3. 10869864 - Combinations for the treatment of cancer (2020-12-22),

4. 10799503 - Methods for the treatment of cancer (2020-10-13),

5. 10682348 - Molecules for administration to ROS1 mutant cancer cells (2020-06-16),

6. 10561651 - Methods for treating neuroblastoma (2020-02-18),

7. 10398693 - Pharmaceutical compositions and dosage forms (2019-09-03),

8. 10357490 - Combinations for the treatment of neuroblastoma (2019-07-23),

9. 10231965 - Molecules for administration to ROS1 mutant cancer cells (2019-03-19),

10. 10085979 - Combinations for the treatment of neuroblastoma (2018-10-02),

11. 10028956 - Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents (2018-07-24),

12. 10017496 - Uracil derivatives as AXL and c-MET kinase inhibitors (2018-07-10),

13. 9987281 - Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor (2018-06-05),

14. 9914731 - Pyrazolo[1,5-a]pyridine derivatives and methods of their use (2018-03-13),

15. 9913827 - Bendamustine derivatives and methods of using same (2018-03-13),

Ignyta, Inc. is a biotechnology company focused on precision medicine. They develop and commercialize targeted therapies for patients with rare cancers. With a mission to conquer cancer through integrated diagnostics and therapeutic solutions, Ignyta combines molecular diagnostics expertise with innovative product development strategies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

25 Patents

#241 in San Diego, CA

#3,150 in California

#13,334 in US

#25,651 in the World

San Diego, CA, United States of America

Ignyta, Inc.

Forward Citations = 102

46 inventors:

Robert L Hudkins (7 out of 72 patents)

Anthony S Drager (5 out of 9 patents)

Reddeppa Reddy Dandu (5 out of 16 patents)

4. Robert E McKean (5 out of 14 patents)

5. Peter D Brown (5 out of 9 patents)

Please report any incorrect information to [email protected]

Loading…